Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as its popular weight-loss and diabetes shots ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right ... Lilly's board of directors approved a $15 billion stock buyback program. CFO Lucas Montarce said of the share buyback ...

Immunocore (IMCR) has appointed Travis Coy as EVP, CFO and Head of Corporate Development, effective January 1. He will become an Executive ...

CFO Lucas Montarce said of the share buyback ... Adam Spatacco has positions in Eli Lilly. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy.